NCT03179410View on ClinicalTrials.gov

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

January 9, 2020

Study Completion Date

December 18, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Avelumab

10 mg/kg intravenously every 2 weeks

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
lead

Andrew J. Armstrong, MD

OTHER

NCT03179410 - PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer | Biotech Hunter | Biotech Hunter